Caribou Biosciences is a biotechnology business based in the US. Caribou Biosciences shares (CRBU) are listed on the NASDAQ and all prices are listed in US Dollars.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $7.43 |
|---|---|
| 52-week range | $4.89 - $13.19 |
| 50-day moving average | $7.80 |
| 200-day moving average | $8.48 |
| Wall St. target price | $29.14 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.64 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.43 from 2023-02-01
| 1 week (2023-01-26) | 7.06% |
|---|---|
| 1 month (2022-12-30) | 18.31% |
| 3 months (2022-11-02) | -21.38% |
| 6 months (2022-08-02) | -7.24% |
| 1 year (2022-02-02) | -29.04% |
|---|---|
| 2 years (2021-01-29) | N/A |
| 3 years (2020-01-29) | N/A |
| 5 years (2018-01-29) | N/A |
| Revenue TTM | $12.7 million |
|---|---|
| Gross profit TTM | $-42,657,000 |
| Return on assets TTM | -13.97% |
| Return on equity TTM | -24.96% |
| Profit margin | 0% |
| Book value | $5.31 |
| Market capitalisation | $423.4 million |
TTM: trailing 12 months
We're not expecting Caribou Biosciences to pay a dividend over the next 12 months.
Caribou Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.